Ranibizumab (Byooviz) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Ranibizumab products are in shortage in Canada (1 of 1 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jun 30, 2027.

An anti-VEGF medicine injected into the eye to treat age-related macular degeneration and other retinal conditions.

Products affected

1 / 1

In shortage since

Jan 1, 2026

Est. full return

Jun 30, 2027

Reports on file

Talk to a pharmacist

Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.

Book a pharmacist appointment

Need your prescription switched?

If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.

See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

Shortage history (red bands = periods in shortage).

Reports by product

Active shortage

BYOOVIZ

10MG · SOLUTION · SAMSUNG BIOEPIS CO., LTD

DIN 02525852 · since Jan 1, 2026, est. end Jun 30, 2027 · The current shortage arises from the delay of contract with new partner followed by the delay in preparing the new supply under the new brand name.

What's happening

Ranibizumab is currently affected by an active shortage report filed with Health Canada by SAMSUNG BIOEPIS CO., LTD.

The reported cause is: the current shortage arises from the delay of contract with new partner followed by the delay in preparing the new supply under the new brand name. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Ranibizumab is classified under “OCULAR VASCULAR DISORDER AGENTS” (ATC S01LA).

Recent changes

No changes recorded yet.

Common questions

What is Ranibizumab used for?

An anti-VEGF medicine injected into the eye to treat age-related macular degeneration and other retinal conditions.

When will Ranibizumab be back in stock in Canada?

The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Ranibizumab in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (ocular vascular disorder agents)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Aflibercept (Zaltrap) No current shortage Brolucizumab (Beovu) No current shortage Verteporfin (Visudyne) Widespread shortage 1 of 1 reported products affected · est. return Dec 31, 2026

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.